Skyepharma competitorsClear all

Skyepharma's top competitors include Recro Gainesville, Durect, Antidote and Amarin.
Skyepharma
Skyepharma
Skyepharma is a drug delivery company developing oral and inhalation products.
Recro Gainesville
Recro Gainesville
Recro Gainesville (also known as Recro Pharma) is a clinical-stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of acute post-operative pain.
Durect
Durect
DURECT is a specialty pharmaceutical company developing innovative drugs for pain and chronic diseases.
Antidote
Antidote
Antidote is accelerating the breakthroughs of new treatments by bridging the gap between medical research and the people who need them.
Amarin
Amarin
Amarin Corporation is a clinical-stage biopharmaceutical company focused on improving the treatment of cardiovascular disease.
Founding Date
Founding Date
1996
Founding Date
2006
Founding Date
N/A
Founding Date
2009
Founding Date
1991
Type
Type
Subsidiary
Type
Public
Type
Public
Type
Private
Type
Public
Tags
Locations
Locations
Saint-Quentin-Fallavier, FR HQ
Locations
Malvern, US HQ
Gainesville, US
Gainesville, US
Locations
Cupertino, US HQ
Locations
London, GB HQ
Carmel, US
New York, US
Locations
Dublin, IE HQ
Dublin, IE
Bridgewater Township, US
Employees
Employees
1413% decrease
Employees
21316% decrease
Employees
902% increase
Employees
522% decrease
Employees
96582% increase
Valuation ($)
Valuation ($)
N/A
Valuation ($)
47.8 m
Valuation ($)
371.8 m
Valuation ($)
N/A
Valuation ($)
1.9 b
Alexa Website Rank
Alexa Website Rank
425641
Alexa Website Rank
359590
Alexa Website Rank
197124
Alexa Website Rank
323566
Alexa Website Rank
436678
Employee Rating
Employee Rating
5
Employee Rating
4.1
Employee Rating
3.5
Employee Rating
3.7
Employee Rating
4.1

Financial

Revenue (est.)
Revenue (est.)
£95.9m (FY, 2015)
Revenue (est.)
$99.2m (FY, 2019)
Revenue (est.)
$29.6m (FY, 2019)
Revenue (est.)
£1.5m (FY, 2018)
Revenue (est.)
$429.8m (FY, 2019)
Cost of goods
Cost of goods
£43.1m (FY, 2015)
Cost of goods
$51m (FY, 2019)
Cost of goods
$4.1m (FY, 2019)
Cost of goods
£1.1m (FY, 2018)
Cost of goods
$96m (FY, 2019)
Gross profit
Gross profit
£52.8m (FY, 2015)
Gross profit
$48.2m (FY, 2019)
Gross profit
$25.4m (FY, 2019)
Gross profit
£447.6k (FY, 2018)
Gross profit
$333.7m (FY, 2019)
Net income
Net income
N/A
Net income
($18.6m) (FY, 2019)
Net income
($20.6m) (FY, 2019)
Net income
(£5.3m) (FY, 2018)
Net income
($22.6m) (FY, 2019)

Funding

Total funding raised
Total funding raised
N/A
Total funding raised
N/A
Total funding raised
$ 20m
Total funding raised
$ 17.9m
Total funding raised
$ 70m
For sources of this data, please see the company profile

View company profiles

Recro Gainesville
HQ
Malvern, US
Employees
213↓ 16% decrease

Recro Gainesville (also known as Recro Pharma) is a clinical-stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of acute post-operative pain.

View company
Durect
HQ
Cupertino, US
Employees
90↑ 2% increase

DURECT is a specialty pharmaceutical company developing innovative drugs for pain and chronic diseases.

View company
Antidote
HQ
London, GB
Employees
52↓ 2% decrease

Antidote is accelerating the breakthroughs of new treatments by bridging the gap between medical research and the people who need them.

View company
Amarin
HQ
Dublin, IE
Employees
965

Amarin Corporation is a clinical-stage biopharmaceutical company focused on improving the treatment of cardiovascular disease.

View company